Home
Diabetes
1 October - 2 October 2013
Diabetes

The global diabetes market is projected to double from $32bn to $64bn over the next 15 years as a result of changing demographics and new therapies entering the clinic.


Now at epidemic levels, diabetes will affect eight percent of the world’s adult population by 2030. As the number of diabetics grows, so too will the need for new treatments to mitigate the effects of diabetes-related disorders and diseases. With this in mind, SAE Media Group is very proud to present our 11th conference focusing on Diabetes, Secondary Complications, Regulation and  Innovation. The conference will take place on the 1st and 2nd October 2013 and will provide a unique platform to engage with industry professionals, KOLs and esteemed academia in the field of diabetic and metabolic disease. With a spotlight on areas such as: combination therapy, diabetic retinopathy, stem cell and islet technology and EU and FDA guidelines, Diabetes 2013 promises to be a truly unmissable event!

FEATURED SPEAKERS

Haya Langerman

Haya Langerman

Medical Advisor, Merck Sharp & Dohme Ltd
Katja Rohwedder

Katja Rohwedder

Medical Director, AstraZeneca GmbH
Natalia Borinshteyn

Natalia Borinshteyn

Head of Diabetes Prevention and Complications, Sanofi-Aventis SA
Peter Feldschreiber

Peter Feldschreiber

Senior Medical Assessor, Four New Square
Philip Ambery

Philip Ambery

Director, Clinical development, Glaxo SmithKline Ltd
Tomas Landh

Tomas Landh

Director, Strategy and Sourcing Diabetes Research Unit, Novo Nordisk A/S

Frederick W K Tam

Reader in Renal Medicine, Imperial College London West London Renal and Transplant Centre Hammersmith Hospital
Frederick W K Tam

Giulio Pasinetti

The Saunders Family Chair and Professor in Neurology, Icahn School of Medicine at Mount Sinai
Giulio Pasinetti

Haya Langerman

Medical Advisor, Merck Sharp & Dohme Ltd
Haya Langerman

Itzik Harosh

President & Chief Executive Officer, Obe Therapy Biotechnology
Itzik Harosh

Dr Itzik Harosh is the founder & CEO of ObeTherapy a biotech dedicated to the discovery of new genes for obesity and diabetes treatment based on the lean phenotype and the development of molecules for the treatment of metabolic syndrome. Establish the concept to look for genes associated to starvation phenotye for the treatment of obesity and type II diabetes.
Priore to the creation of ObeTherapy he was a Group leader in GSK in France where he learned the art of drug discovery, targets identification and validation.
Dr. Harosh did his PhD at The Weizmann Institute of Science in Israel, working on DNA repair enzymes which was followed by four years of post doctoral experience at Stanford and at Davis University, California, US. From there he moved to France where he worked in the CNRS at the laboratory of Miro Radman. Dr. Harosh is the author and co-author of 15 articles and 8 patents all dealing with obesity, diabetes and HTS.
Dr. Harosh is on the editorial board of; Journal of US-China Medical Science and is regularly invited to international Obesity, Diabetes and metabolic syndrome conferences.
Before the creation of ObeTherapy, Itzik was a Group leader in GSK where he learned the art of drug discovery, targets identification and validation. Itzik also has four years of post doctoral experience at Stanford and the University of California at Davis working on DNA repair.

John Warren

Director, Medicines Assessment Ltd
John Warren

Katja Rohwedder

Medical Director, AstraZeneca GmbH
Katja Rohwedder

Mohammad Al-Ubaydli

CEO, Patients Know Best
Mohammad Al-Ubaydli

Nagy Habib

Professor Department of Surgery & Cancer, Imperial College London
Nagy Habib

Natalia Borinshteyn

Head of Diabetes Prevention and Complications, Sanofi-Aventis SA
Natalia Borinshteyn

Nigel Sansom

Managing Director, Celaris Biosystems
Nigel Sansom

Peter Feldschreiber

Senior Medical Assessor, Four New Square
Peter Feldschreiber

Philip Ambery

Director, Clinical development, Glaxo SmithKline Ltd
Philip Ambery

Rebecca Taub

CEO, Madrigal Pharmaceuticals
Rebecca Taub

Timothy Broke-Smith

Chief Operating Officer, Diabetology
Timothy Broke-Smith

Tomas Landh

Director, Strategy and Sourcing Diabetes Research Unit, Novo Nordisk A/S
Tomas Landh

Wim Wientjens

Ambassador, International Diabetes Federation
Wim  Wientjens

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Philip Ambery

Philip Ambery, Director, Clinical development, Glaxo SmithKline Ltd

John Warren

John Warren, Director, Medicines Assessment Ltd

clock

9:10

From concept to clinical practice: therapeutic targets to reduce disease in type 2 diabetes

Philip Ambery

Philip Ambery, Director, Clinical development, Glaxo SmithKline Ltd

  • Learnings about the pathophysiology of diabetic complications
  • Can these learnings deliver potential new drug targets? (data from early / mechanistic studies)
  • Are there common targets between Type 1 and 2 diabetes?
  • clock

    9:50

    Thinking outside the box: For the identification of novel targets for diabetes treatment

    Itzik Harosh, President & Chief Executive Officer, Obe Therapy Biotechnology

  • Past and present gene targets in obesity and diabetes
  • Starvation phenotype as source for new gene targets for diabetes treatment
  • Rare genetic diseases as a clue for identification of new targets for common metabolic syndrome
  • Knock-out of the enteropeptidase gene in mice
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Innovation in Diabetes: needs, trends and outcome

    Tomas Landh

    Tomas Landh, Director, Strategy and Sourcing Diabetes Research Unit, Novo Nordisk A/S

  • Current challenges associated with drug development
  • New strategic modes of accessing innovation
  • Trends and outcome measures
  • Future of innovation
  • clock

    11:40

    Diabetes: future medicine and the role of synthetic biology

    Nigel Sansom

    Nigel Sansom, Managing Director, Celaris Biosystems

  • State of the Art and the story so far
  • Prospects for synthetic biology as a viable treatment
  • Possible future therapeutics
  • clock

    12:20

    Networking Lunch

    clock

    13:40

    Diabetology: oral delivery of insulin and other diabetes therapies

    Timothy Broke-Smith

    Timothy Broke-Smith, Chief Operating Officer, Diabetology

  • Axcess™ convenient oral delivery of peptides that would otherwise require injection: how it works and the benefits it can provide
  • Capsulin™ oral insulin: clinical progress and strengths for treating diabetes
  • Oral GLP-1 and other oral antidiabetic therapies in development
  • clock

    14:20

    Diabetes...So What? Serious and up-to-date answers to this question

    Wim  Wientjens

    Wim Wientjens, Ambassador, International Diabetes Federation

  • Three processes, three roles
  • Being a normal member of society
  • Insulin and injection systems
  • The Health Care Inspectorate
  • The false hope of an international care standard
  • clock

    15:00

    Afternoon Tea

    clock

    15:30

    A toolkit for CCGs to put their diabetes pathways under patient control

    Mohammad Al-Ubaydli

    Mohammad Al-Ubaydli, CEO, Patients Know Best

  • The patient is the one with the data and the one making the decisions day-to-day
  • Diabetes clinicians should be at the forefront of putting the patient in control of data and decisions
  • Patient control brings consumer-level prices and usability into health care
  • clock

    16:10

    Vitamin D and diabetic nephropathy

    Frederick W K Tam

    Frederick W K Tam, Reader in Renal Medicine, Imperial College London West London Renal and Transplant Centre Hammersmith Hospital

  • Vitamin D and the immune system
  • Vitamin D – effect on progression of diabetic nephropathy
  • Variation in vitamin D – a potential confounding factor in clinical trials
  • clock

    16:50

    Chairman's closing remarks and end of Day One

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Peter Feldschreiber

    Peter Feldschreiber, Senior Medical Assessor, Four New Square

    John Warren

    John Warren, Director, Medicines Assessment Ltd

    clock

    9:10

    Benefit: risk as seen by the regulator and the court

    Peter Feldschreiber

    Peter Feldschreiber, Senior Medical Assessor, Four New Square

  • Risk/benefit assessments: clinical prognostic risk, socio-economic and environmental risks, consumer protection, intellectual property, commercial risks and risk of criminal sanctions
  • Risk/benefit profile: current international legislation and regulatory objectives for medicinal products
  • Examples of regulatory failure: Vioxx, Seroxat, the glitazones and TGN1412
  • clock

    9:50

    Cardiovascular risk in diabetes: shifting regulatory perspective

    John Warren

    John Warren, Director, Medicines Assessment Ltd

  • FDA's response to Glitazones
  • FDA's response to obesity drugs
  • Litigation and risk >2
  • EU regulatory position
  • Implications of cardiovascular safety threshold for efficacy assessment
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    MGL-3196 liver-directed thyroid hormone beta agonist, a novel treatment for diabetic dyslipdemia

    Rebecca Taub

    Rebecca Taub, CEO, Madrigal Pharmaceuticals

  • Diabetes is associated with a dyslipidemia characterized by fatty liver, elevated triglycerides (TGs), atherogenic LDL particles and low HDL cholesterol.
  • Fatty liver is a cause of liver insulin resistance and non-alcoholic steatohepatitis (NASH) and is associated with increased CV disease. 
  • MGL-3196 reduces LDL cholesterol and triglycerides in Phase 1 studies in humans, and also reduced fatty liver in preclinical models of fatty liver disease

  •  

    clock

    11:40

    Manipulation of a short-activating RNA oligonucleotide targeting the islet ß-cell transcriptional factor MafA in CD34+ cells

    Nagy Habib

    Nagy Habib, Professor Department of Surgery & Cancer, Imperial College London

  • Bioengineering surrogate insulin producing cells, an alternative replacement strategy
  • A novel approach using short-activating RNA oligonucleotides
  • Transfecting RNA to increase transcript levels of the master regulator of insulin biosynthesis
  • Developing insulin producing surrogate cells for treating diabetes
  • clock

    12:20

    Networking Lunch

    clock

    13:50

    Diabetes secondary complication: hypoglycaemia

    Haya Langerman

    Haya Langerman, Medical Advisor, Merck Sharp & Dohme Ltd

  • What is it?
  • What are the consequences?
  • Improving the management of hypoglycaemia in type 2 diabetes
  • Insight into the SU pharmacy survey
  • clock

    14:30

    Dapagliflozin vs Glipizide as add-on therapy in patients with Type 2 diabetes

    Katja Rohwedder

    Katja Rohwedder, Medical Director, AstraZeneca GmbH

    clock

    15:10

    Afternoon Tea

    clock

    15:40

    Epigenetic mechanisms linking diabetes and synaptic impairment in Alzheimer’s disease and other forms of dementia

  • Differential regulation of epigenetic modifier histone deacetylase (HDAC) IIa is associated with impaired synaptic integrity in the brains of diabetic Alzheimer’s disease subjects
  • In experimental model of diabetes, diabetic condition promotes HDAC IIa in the brain; prolonged diabetic condition is associated with increased susceptibility to neurodegeneration
  • Pharmacological Inhibition of HDAC IIa in diabetes restores synaptic function, promotes synaptic plasticity, and enhances learning and memory functions
     
  • Giulio Pasinetti

    Giulio Pasinetti, The Saunders Family Chair and Professor in Neurology, Icahn School of Medicine at Mount Sinai

    clock

    16:20

    PANEL DISCUSSION: Microvascular Complications of diabetes: major burden & unmet need

  • Current considerations and major challenges of early diagnosis and management of Diabetic nephropathy, Neuropathy, Foot Ulcer & Retinopathy
  • Disease modifying therapy:
  • Is it possible to halt or reverse complications?
  • How can that be accomplished?
  • How Academia, Industry and Advocacy groups can work together to address this unmet medical need?
  • What lies ahead for the future?
     
  • Haya Langerman

    Haya Langerman, Medical Advisor, Merck Sharp & Dohme Ltd

    Peter Feldschreiber

    Peter Feldschreiber, Senior Medical Assessor, Four New Square

    John Warren

    John Warren, Director, Medicines Assessment Ltd

    clock

    17:00

    Chairman’s Closing Remarks and Close of Day Two


    Director
    Medicines Assessment Ltd
    Senior Medical Assessor
    Four New Square
    Director, Clinical development
    Glaxo SmithKline Ltd
    Director, Strategy and Sourcing Diabetes Research Unit
    Novo Nordisk A/S
    Ambassador
    International Diabetes Federation
    Professor Department of Surgery & Cancer
    Imperial College London
    Medical Director
    AstraZeneca GmbH
    Reader in Renal Medicine
    Imperial College London West London Renal and Transplant Centre Hammersmith Hospital
    CEO
    Madrigal Pharmaceuticals
    President & Chief Executive Officer
    Obe Therapy Biotechnology
    Medical Advisor
    Merck Sharp & Dohme Ltd
    Managing Director
    Celaris Biosystems
    CEO
    Patients Know Best
    Head of Diabetes Prevention and Complications
    Sanofi-Aventis SA
    Chief Operating Officer
    Diabetology
    The Saunders Family Chair and Professor in Neurology
    Icahn School of Medicine at Mount Sinai

    Marriott Regents Park

    128 King Henry's Road
    London NW3 3ST
    United Kingdom

    Marriott Regents Park

    This 4 star north London hotel in zone 2 is the perfect destination for the astute business traveler as well as the leisure guest that knows how convenient north London hotels are, as a base from which to explore the city .Bond Street is just 3 stops from Swiss Cottage underground station on the Jubilee Line, so you can be shopping, exploring the sights and taking in one of London’s world-renowned West End shows in less than 15 minutes when you stay at this hotel near central London. At the same time, the hive of activity that is Camden Town, the chic shops, cafes and restaurants of Primrose Hill and ZSL’s London Zoo in Regents Park are all just a short walk from this hotel in north London.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.